Triglyceride–rich lipoproteins, apolipoproteins, and atherosclerotic cardiovascular events among patients with diabetes mellitus and end–stage renal disease on hemodialysis
The American Journal of Cardiology Jun 10, 2021
Lamprea–Montealegre JA, Katz R, Scharnagl H, et al. - This study attempted to explore the incident atherosclerotic cardiovascular disease (ASCVD) events, defined as myocardial infarction, ischemic stroke, or a coronary revascularization procedure, among 1255 participants with type 2 diabetes and end–stage renal disease (ESRD) treated with hemodialysis in this post–hoc analysis of the “Die Deutsche Diabetes Dialyse Studie (4D)” clinical trial. Researchers applied Cox–regression methods to analyze the correlation of triglycerides, very–low density lipoprotein cholesterol, and apolipoproteins B (Apo B) and C–III (Apo C–III) with ASCVD. There was no evidence that triglycerides, triglyceride–rich lipoproteins, or apolipoproteins B or C–III were correlated with risk of ASCVD events among patients with type 2 diabetes and ESRD on hemodialysis. The data imply that lowering triglycerides may not reduce atherosclerotic cardiovascular risk in this population.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries